Dynavax Technologies Corp
DVAX10.860USD
-0.120-1.09%
Market hours （ET）Quotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM
More Details of Dynavax Technologies Corp Company
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Company Info
Ticker SymbolDVAX
Company nameDynavax Technologies Corp
IPO dateFeb 19, 2004
CEOMr. Ryan Spencer
Number of employees405
Security typeOrdinary Share
Fiscal year-endFeb 19
Address2100 Powell Street
CityEMERYVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94608
Phone15108485100
Websitehttps://www.dynavax.com/
Ticker SymbolDVAX
IPO dateFeb 19, 2004
CEOMr. Ryan Spencer
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+30.19%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+32.77%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+35.83%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
By RegionUSD
Name
Revenue
Proportion
US
67.81M
99.47%
Non-US
358.00K
0.53%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.52%
Hedge Fund
38.07%
Investment Advisor/Hedge Fund
21.73%
Research Firm
5.56%
Pension Fund
1.34%
Individual Investor
0.59%
Sovereign Wealth Fund
0.57%
Bank and Trust
0.55%
Venture Capital
0.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
551
130.99M
109.09%
-16.02M
2025Q1
575
132.57M
110.30%
-15.70M
2024Q4
565
133.92M
107.04%
-18.98M
2024Q3
561
132.88M
101.45%
-18.82M
2024Q2
547
135.21M
103.33%
-14.69M
2024Q1
545
136.49M
104.51%
-4.07M
2023Q4
529
128.50M
99.42%
-9.47M
2023Q3
515
128.65M
99.89%
-9.14M
2023Q2
503
129.32M
100.65%
-12.27M
2023Q1
497
129.65M
101.54%
-1.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
18.65M
15.53%
-799.41K
-4.11%
Mar 31, 2025
Deep Track Capital LP
17.79M
14.82%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.67M
7.22%
-459.90K
-5.04%
Mar 31, 2025
State Street Global Advisors (US)
6.79M
5.65%
-1.00M
-12.88%
Mar 31, 2025
Tang Capital Management, LLC
5.75M
4.79%
+3.90M
+210.81%
Mar 31, 2025
Chicago Capital, LLC
5.34M
4.45%
-36.81K
-0.68%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
4.32%
-2.33K
-0.04%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.01M
3.34%
-58.27K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.07M
2.55%
+71.47K
+2.39%
Mar 31, 2025
Renaissance Technologies LLC
2.71M
2.25%
+350.25K
+14.87%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Biotechnology & Genome ETF
2.7%
Virtus LifeSci Biotech Products ETF
1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.15%
ETC 6 Meridian Small Cap Equity ETF
0.79%
Invesco S&P SmallCap Health Care ETF
0.79%
Franklin Genomic Advancements ETF
0.64%
Themes US Small Cap Cash Flow Champions ETF
0.45%
SPDR S&P Biotech ETF
0.41%
Royce Quant Small-Cap Quality Value ETF
0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.29%
View more
Invesco Biotechnology & Genome ETF
Proportion2.7%
Virtus LifeSci Biotech Products ETF
Proportion1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.15%
ETC 6 Meridian Small Cap Equity ETF
Proportion0.79%
Invesco S&P SmallCap Health Care ETF
Proportion0.79%
Franklin Genomic Advancements ETF
Proportion0.64%
Themes US Small Cap Cash Flow Champions ETF
Proportion0.45%
SPDR S&P Biotech ETF
Proportion0.41%
Royce Quant Small-Cap Quality Value ETF
Proportion0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
Proportion0.29%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
